Although the acquisition did receive as much attention as the merger between Aphria and Tilray, Inc.
Jazz’s management team is executing on a strategy that is focused on creating an innovative, high-growth, global biopharma leader in neuroscience that has a global footprint.
For Jazz, the most attractive asset from GW is Epidiolex, a high-growth commercial product that has near-term blockbuster potential.
This amount of revenue was derived from the US market and GW’s recent expansion in Europe should serve as a near-term growth driver.
Jazz’s cash flow profile provides the capability to rapidly de-leverage to a target net leverage of less than 3.5x by the end of 2022.
All information that we provide is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.